This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant.
Fanconi's disease is characterised by a constitutional defect in DNA repair which results in the occurrence of bone marrow failure and haematological malignancies, mainly myeloid: at the age of 40, the cumulative incidence of these two types of pathology reaches almost 100%. The only curative treatment for haemtalogocial diseases is allogenic hematopoietic stem cell transplant. Transplantation modalities must be adapted to the particular susceptibility of these patients to DNA bridging agents and radiotherapy. HSC transplantation is indicated with an unaffected matched related or matched unrelated donor when the patient has severe bone marrow failure or a poor prognostic clonal evolution (cytogenetic evolution or proven haemopathy). Alternative transplants (9/10 pheno-identical, haplo-identical and placental blood donors) were no longer proposed in most cases due to the frequency of severe complications (graft-versus-host disease, viral infections) and the catastrophic medium-term survival of around 40% (Dufort, Bone Marrow Transplant 2012, Gluckman Biol Blood Marrow Transplant. 2007). The development over the last decade of new haploidentical or phenoidentical 9/10 transplant protocols with unmodified grafts and GVH prophylaxis with post-transplant cyclosphosphamide or ex vivo T-depletion adapted to the particular susceptibility of patients with Fanconi disease has reduced the incidence of these severe complications. This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant
Study Type
OBSERVATIONAL
Enrollment
18
Additional blood samples at J100, M6, M12, M24
Overall Survival Rate
Time frame: 2 years after transplant
Engraftment
Engraftment at least 3 consecutive days with neutrophils \> 0.5 G/L and 7 consecutive days with platelets \> 20 G/L, with predominantly whole blood donor chimerism
Time frame: At day 100
Absolute neutrophils count
Time frame: At 1 month
Absolute neutrophils count
Time frame: At 3 months
Absolute neutrophils count
Time frame: At 6 months
Absolute neutrophils count
Time frame: At 12 months
Absolute neutrophils count
Time frame: At 24 months
Absolute number of platelets
Time frame: At 1 month
Absolute number of platelets
Time frame: At 3 months
Absolute number of platelets
Time frame: At 6 months
Absolute number of platelets
Time frame: At 12 months
Absolute number of platelets
Time frame: At 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence of grade 2 to 4 Acute Graft versus Host Disease
Time frame: At 3 months
Incidence of Acute cortico-resistant Graft versus Host Disease
Time frame: At 3 months
Incidence of Chronic Graft versus Host Disease
Time frame: At 24 months
Incidence of relapse
Time frame: At 12 months
Incidence of relapse
Time frame: At 24 months
Progression free survival
Time frame: At 12 months
Progression free survival
Time frame: At 24 months
Incidence of reactivation of cytomegalovirus infection
Time frame: At 12 months
Incidence of reactivation of Epstein Barr virus infection
Time frame: At 12 months
Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: At 3 months
Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: At 6 months
Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: At 12 months
Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: At 24 months
Graft-versus-host disease-free, relapse-free survival (GRFS)
Time frame: At 24 months
Incidence of cardiac toxities
Time frame: At 12 months
Overall survival
Time frame: At 12 months
Quality of Life questionnaire for adults
Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Time frame: At inclusion
Quality of Life questionnaire for adults
Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Time frame: At 3 months
Quality of Life questionnaire for adults
Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Time frame: At 6 months
Quality of Life questionnaire for adults
Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Time frame: At 12 months
Quality of Life questionnaire for adults
Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Time frame: At 24 months
Quality of life questionnaire for minors
Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning.
Time frame: At inclusion
Quality of life questionnaire for minors
Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning.
Time frame: At 3 months
Quality of life questionnaire for minors
Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning.
Time frame: At 6 months
Quality of life questionnaire for minors
Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning.
Time frame: At 12 months
Quality of life questionnaire for minors
Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning.
Time frame: At 24 months
Rate of chimerism
Time frame: At 1 month
Rate of chimerism
Time frame: At 3 months
Rate of chimerism
Time frame: At 6 months
Rate of chimerism
Time frame: At 12 months
Rate of chimerism
Time frame: At 24 months
Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood
Time frame: 3 months after transplant
Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood
Time frame: 6 months after transplant
Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood
Time frame: 12 months after transplant
Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood
Time frame: 24 months after transplant
Ferritine levels
Time frame: At 3 months
Ferritine levels
Time frame: At 6 months
Ferritine levels
Time frame: At 12 months
Ferritine levels
Time frame: At 24 months